Quartz·1 min read·easy

Amgen is raising its outlook after beating earnings and dropping a weight loss drug

Cris Tolomia
AI Summary

Biotech firm Amgen has raised its full-year revenue forecast to a range of $38.2 billion to $39.4 billion. This follows a strong second quarter where the company saw a 10% increase in revenue to $10.1 billion.

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealtheconomy

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in

Amgen is raising its outlook after beating earnings and dropping a weight loss drug — Headlinne — headlinne